Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

Prediction of hub genes of Alzheimer's disease using a protein interaction network and functional enrichment analysis

  • Wee, Jia Jin (Faculty of Health and Life Sciences, Management and Science University) ;
  • Kumar, Suresh (Faculty of Health and Life Sciences, Management and Science University)
  • Received : 2020.08.18
  • Accepted : 2020.09.30
  • Published : 2020.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Alzheimer's disease (AD) is a chronic, progressive brain disorder that slowly destroys affected individuals' memory and reasoning faculties, and consequently, their ability to perform the simplest tasks. This study investigated the hub genes of AD. Proteins interact with other proteins and non-protein molecules, and these interactions play an important role in understanding protein function. Computational methods are useful for understanding biological problems, in particular, network analyses of protein-protein interactions. Through a protein network analysis, we identified the following top 10 hub genes associated with AD: PTGER3, C3AR1, NPY, ADCY2, CXCL12, CCR5, MTNR1A, CNR2, GRM2, and CXCL8. Through gene enrichment, it was identified that most gene functions could be classified as integral to the plasma membrane, G-protein coupled receptor activity, and cell communication under gene ontology, as well as involvement in signal transduction pathways. Based on the convergent functional genomics ranking, the prioritized genes were NPY, CXCL12, CCR5, and CNR2.

Keywords

References

  1. Mendez MF. Early-onset Alzheimer's disease. Neurol Clin 2017;35:263-81. https://doi.org/10.1016/j.ncl.2017.01.005
  2. What happens to the brain in Alzheimer's disease? Bethesda: National Institute on Aging, 2017. Accessed 2019 Dec 25. Available from: https://www.nia.nih.gov/health/what-happens-brain-alzheimers-disease.
  3. Sulkava S, Muggalla P, Sulkava R, Ollila HM, Peuralinna T, Myllykangas L, et al. Melatonin receptor type 1A gene linked to Alzheimer's disease in old age. Sleep 2018;41:zsy103.
  4. Huang HC, Jiang ZF. Accumulated amyloid-β peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J Alzheimers Dis 2009;16:15-27. https://doi.org/10.3233/JAD-2009-0960
  5. LaFerla FM, Oddo S. Alzheimer's disease: Aβ, tau, and synaptic dysfunction. Trends Mol Med 2005;11:170-176. https://doi.org/10.1016/j.molmed.2005.02.009
  6. Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, et al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease. Neuron 2018;100:1337-1353. https://doi.org/10.1016/j.neuron.2018.10.031
  7. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63:287-303. https://doi.org/10.1016/j.neuron.2009.06.026
  8. Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013;153:707-720. https://doi.org/10.1016/j.cell.2013.03.030
  9. Jiang W, Zhang Y, Meng F, Lian B, Chen X, Yu X, et al. Identification of active transcription factor and miRNA regulatory pathways in Alzheimer's disease. Bioinformatics 2013;29:2596-2602. https://doi.org/10.1093/bioinformatics/btt423
  10. Pinero J, Ramirez-Anguita JM, Sauch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res 2020;48:D845-D855.
  11. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-2504. https://doi.org/10.1101/gr.1239303
  12. The UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res 2015;43:204-212. https://doi.org/10.1093/nar/gku989
  13. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019;47:D607-D613. https://doi.org/10.1093/nar/gky1131
  14. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 2014;8 Suppl 4:S11. https://doi.org/10.1186/1752-0509-8-S4-S11
  15. Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, et al. FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics 2015;15:2597-2601. https://doi.org/10.1002/pmic.201400515
  16. Maingret V, Barthet G, Deforges S, Jiang N, Mulle C, Amedee T. PGE2-EP3 signaling pathway impairs hippocampal presynaptic long-term plasticity in a mouse model of Alzheimer's disease. Neurobiol Aging 2017;50:13-24. https://doi.org/10.1016/j.neurobiolaging.2016.10.012
  17. Slawik H, Volk B, Fiebich B, Hull M. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem Int 2004;45:653-660. https://doi.org/10.1016/j.neuint.2004.04.007
  18. Koide S, Onishi H, Hashimoto H, Kai T, Yamagami S. Plasma neuropeptide Y is reduced in patients with Alzheimer's disease. Neurosci Lett 1995;198:149-151. https://doi.org/10.1016/0304-3940(95)11973-Z
  19. Grammas P, Roher AE, Ball MJ. Increased accumulation of cAMP in cerebral microvessels in Alzheimer's disease. Neurobiol Aging 1994;15:113-116. https://doi.org/10.1016/0197-4580(94)90151-1
  20. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001;4:702-710. https://doi.org/10.1038/89490
  21. Parachikova A, Cotman CW. Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease. Neurobiol Dis 2007;28:143-153. https://doi.org/10.1016/j.nbd.2007.07.001
  22. Li T, Zhu J. Entanglement of CCR5 and Alzheimer's disease. Front Aging Neurosci 2019;11:209. https://doi.org/10.3389/fnagi.2019.00209
  23. Combarros O, Infante J, Llorca J, Pena N, Fernandez-Viadero C, Berciano J. The chemokine receptor CCR5-Delta32 gene mutation is not protective against Alzheimer's disease. Neurosci Lett 2004;366:312-314. https://doi.org/10.1016/j.neulet.2004.05.058
  24. Micale V, Mazzola C, Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol Res 2007;56:382-392. https://doi.org/10.1016/j.phrs.2007.09.008
  25. Richards G, Messer J, Faull RL, Stadler H, Wichmann J, Huguenin P, et al. Altered distribution of mGlu2 receptors in beta-amyloid-affected brain regions of Alzheimer cases and aged PS2APP mice. Brain Res 2010;1363:180-190. https://doi.org/10.1016/j.brainres.2010.09.072
  26. Vendramini AA, de Labio RW, Rasmussen LT, Dos Reis NM, Minett T, Bertolucci PH, et al. Interleukin-8-251T > A, interleukin-1alpha-889C > T and apolipoprotein E polymorphisms in Alzheimer's disease. Genet Mol Biol 2011;34:1-5.
  27. Elkahloun AG, Hafko R, Saavedra JM. An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease. Alzheimers Res Ther 2016;8:5. https://doi.org/10.1186/s13195-015-0167-5
  28. Pang X, Zhao Y, Wang J, Zhou Q, Xu L, Kang D, et al. The bioinformatic analysis of the dysregulated genes and microRNAs in entorhinal cortex, hippocampus, and blood for Alzheimer's disease. Biomed Res Int 2017;2017:9084507.
  29. Bae SH, Kim HW, Shin S, Kim J, Jeong YH, Moon J. Decipher reliable biomarkers of brain aging by integrating literature-based evidence with interactome data. Exp Mol Med 2018;50:28.
  30. Kim BY, Lim HS, Kim Y, Kim YJ, Koo I, Jeong SJ. Evaluation of animal models by comparison with human late-onset Alzheimer's disease. Mol Neurobiol 2018;55:9234-9250. https://doi.org/10.1007/s12035-018-1036-6
  31. Lanke V, Moolamalla STR, Roy D, Vinod PK. Integrative analysis of hippocampus gene expression profiles identifies network alterations in aging and Alzheimer's disease. Front Aging Neurosci 2018;10:153. 29875655 https://doi.org/10.3389/fnagi.2018.00153
  32. Vargas DM, De Bastiani MA, Zimmer ER, Klamt F. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates. Alzheimers Res Ther 2018;10:59. https://doi.org/10.1186/s13195-018-0394-7
  33. Xiang S, Huang Z, Wang T, Han Z, Yu CY, Ni D, et al. Condition-specific gene co-expression network mining identifies key pathways and regulators in the brain tissue of Alzheimer's disease patients. BMC Med Genomics 2018;11:115. https://doi.org/10.1186/s12920-018-0431-1
  34. Yan T, Ding F, Zhao Y. Integrated identification of key genes and pathways in Alzheimer's disease via comprehensive bioinformatical analyses. Hereditas 2019;156:25. https://doi.org/10.1186/s41065-019-0101-0
  35. Wu M, Fang K, Wang W, Lin W, Guo L, Wang J. Identification of key genes and pathways for Alzheimer's disease via combined analysis of genome-wide expression profiling in the hippocampus. Biophys Rep 2019;5:98-109. https://doi.org/10.1007/s41048-019-0086-2